申请人:Signature Therapeutics, Inc.
公开号:US20140206597A1
公开(公告)日:2014-07-24
The embodiments provide prodrug compounds of Formulae I-XV. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XV that provides controlled release of an opioid. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
本实施例提供了公式I-XV的前药化合物。本公开还提供了组合物及其使用方法,其中组合物包括公式I-XV的前药化合物,该化合物提供阿片类物质的控制释放。这样的组合物可以选择性地提供胰蛋白酶抑制剂,该抑制剂与介导前药中阿片类物质控制释放的酶相互作用,以减弱对前药的酶解作用。